Abstract:During tumorigenesis and progression, the immune checkpoint programmed death-1 (PD-1) and its ligand programmed death ligand-1 (PD-L1) play critical roles in suppressing T cell-mediated anticancer immune responses, leading to T-cell exhaustion and subsequent tumor evasion. Therefore, anti-PD-L1/PD-1 therapy has been an attractive strategy for treating cancer over the past decade. However, the overall efficacy of this approach remains suboptimal, revealing an urgent need for novel insights. Interestingly, increasing evidence indicates that both PD-L1 on tumor cells and PD-1 on tumor-specific T cells undergo extensive N-linked glycosylation, which is essential for the stability and interaction of these proteins, and this modification promotes tumor evasion. In various preclinical models, targeting the N-linked glycosylation of PD-L1/PD-1 was shown to significantly increase the efficacy of PD-L1/PD-1 blockade therapy. Furthermore, deglycosylation of PD-L1 strengthens the signal intensity in PD-L1 immunohistochemistry (IHC) assays, improving the diagnostic and therapeutic relevance of this protein. In this review, we provide an overview of the regulatory mechanisms underlying the N-linked glycosylation of PD-L1/PD-1 as well as the crucial role of N-linked glycosylation in PD-L1/PD-1-mediated immune evasion. In addition, we highlight the promising implications of targeting the N-linked glycosylation of PD-L1/PD-1 in the clinical diagnosis and treatment of cancer. Our review identifies knowledge gaps and sheds new light on the cancer research field.

Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave

The Regulation of N6‐methyladenosine Modification in PD‐L1‐induced Anti‐tumor Immunity

[Regulation of PD-L1 posttranslational modification and its application progress in tumor immunotherapy]

Anti-Tumor Potential of Post-Translational Modifications of PD-1

The Nuclear Transportation of PD-L1 and the Function in Tumor Immunity and Progression

Post-translational Modification of PD-1: Potential Pathways for Cancer Immunotherapy

Regulation of post-translational modification of PD-L1 and associated opportunities for novel small-molecule therapeutics

Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways

New horizons in the mechanisms and therapeutic strategies for PD-L1 protein degradation in cancer

PD-1 regulation in immune homeostasis and immunotherapy

Posttranslational regulatory mechanism of PD-L1 in cancers and associated opportunities for novel small-molecule therapeutics

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

Regulation of PD-L1 expression in the tumor microenvironment

Unleashing the power of immune checkpoints: Post-translational modification of novel molecules and clinical applications

Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy

Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics

Recent advances and mechanisms of action of PD-L1 degraders as potential therapeutic agents

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

N-linked glycosylation of PD-L1/PD-1: an emerging target for cancer diagnosis and treatment

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PDL1 blockade